Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Biocartis forum geopend
Volgen
For those of you that read further into the linked article, there is a comparison of NGS v Idylla costs that I think is very unfair. It compares the "reagent costs" of Idylla vs NGS and finds them roughly comparable. However, when they looked at running multiple assays for NSCLC that may have several molecular drivers they found Idylla to be more expensive. I think this is unfair since it assumes the use of an onsite ThermoFisher NGS system and does not account for the labor necessary to run the analyses. NGS requires many steps so the labor costs are not negligible, Secondly, the initial costs of placement of the NGS equipment has associated costs that are often an order of magnitude higher. The NGS costs of analysis at an offsite contracted lab would undoubtedly be much higher. FL
Flatlander schreef op 19 juni 2021 00:12 :
For those of you that read further into the linked article, there is a comparison of NGS v Idylla costs that I think is very unfair. It compares the "reagent costs" of Idylla vs NGS and finds them roughly comparable. However, when they looked at running multiple assays for NSCLC that may have several molecular drivers they found Idylla to be more expensive.
I think this is unfair since it assumes the use of an onsite ThermoFisher NGS system and does not account for the labor necessary to run the analyses. NGS requires many steps so the labor costs are not negligible, Secondly, the initial costs of placement of the NGS equipment has associated costs that are often an order of magnitude higher. The NGS costs of analysis at an offsite contracted lab would undoubtedly be much higher.
FL
Why don,t biocartis counter-attack to defend their product?
Kojo2 schreef op 18 juni 2021 15:01 :
@ Stefzele,
@ Hopende,
Nu bevestigd wordt dat het koersherstel van de laatste dagen zich niet kan doorzetten hou ik me klaar om terug in Biocartis te stappen. Liefst onder de € 3,90, voor een kort ritje van 4 à 5%.
Niet haalbaar voor mij want zou er op neerkomen om een extra 10000€ te investeren in biocartis om 300€ over te houden en ik ben niet zeker hoe diep ze nog zullen gaan
Hopende schreef op 19 juni 2021 10:41 :
[...]
Why don,t biocartis counter-attack to defend their product?
Hopende I'm not aware of BCART's IR Dept ever going on the offensive like that. The article was a huge positive on whole, by confirming that Idylla was being implemented during the pandemic to keep labs operating in a socially distanced manner and I don't believe IR ever mentioned it. The cost issues are pretty transparent by the wording of comparison of only the "reagent" costs. It has been said numerous time that the pandemic was accelerating changes that were already underway. If this is true then it should benefit adoption rates, FL
www.ncbi.nlm.nih.gov/pmc/articles/PMC... from the UK "The Idylla™ EGFR Mutation Test compared with cobas and therascreen PCR assays alone (34 cases) showed 100% concordance. Thus, if NGS cases were excluded from the analysis, this gives an estimated technical sensitivity and specificity of 100%. The main aim of this study was to compare the Idylla with routine PCR because this is probably still the most widely used methodology in Europe (NGS panels are rarely CE approved). The results demonstrate that Idylla is at least as good as the standard care CE–marked testing that is in common use. In light of the fact that the majority of centres are probably still using PCR-based tests, it can be said that the Idylla™ EGFR Mutation Test performs equally well as standard care tests for the majority of common and well-characterised lung cancer EGFR mutations. The system also offers significant advantages in terms of turn-around times. With the future shift to NGS being extremely likely, some centres may opt for a rapid PCR-based EGFR screening test initially in urgent cases and follow this up with NGS later. In this scenario, the Idylla™ would be best suited. NICE primarily recommends using FFPE tumour biopsy tissue for EGFR testing, but acknowledges that often these samples are very small and that testing cytological material may be useful where no tissue is available after the histological assessment has been carried out [5]. A larger study that includes cytological and fresh tissue samples with Idylla™ may therefore be warranted. NICE does not specifically comment on the financial implications of different testing modalities. The Idylla™ EGFR Mutation Test costs around £170 per test (Europe-wide average, depending on pricing structure) and is therefore comparable with most conventional EGFR PCR assays. In comparison, the cost of NGS gene panels is currently around £300. Therefore, depending on the local arrangements, Idylla™ could potentially reduce costs for some institutions, but for others, this might not be cost effective and the additional financial commitment would need to be balanced against the clinical benefits of reduced turn-around time (which may also be cost saving). A full health economics evaluation of molecular testing in lung cancer could be very helpful." FL
Dank u wel,FL!2 positieve artikels over Biocartis,dit kunnen we als aandeelhouders gebruiken.Om de koers positief te ondersteunen is er m.i meer nodig Opening markt Japan, Doorbraak in China of een FDA approval,al dan niet gevolgd door een kapitaal operatie of notering op Nasdaq.De koersontwikkeling van de laatste maanden geeft m.i. ook aan dat we daar op zitten te wachten! Een Ko of Nasdaq notering zou positief uitdraaien voor het aandeel, aangezien er onzekerheid inzake de financiering van de komende jaren zou verdwijnen.Nogmaals dank voor uw steeds positieve bijdrage, hopelijk komt er gauw een doorbraak
CGCDLR The MDx investing environment is difficult right now. The next couple earnings reports for BCART are important since they presumably have a bit of a tailwind coming out of the pandemic (if the 1st article summarized is to be believed and can be extrapolated to other MDx labs). There are a number of catalysts expected in the next year. If the market believes that the road to profitability is accelerating from the 2024 analyst consensus then the SP will follow. FL
Verwacht iemand iets van de kepler belgian science day deze namiddag
Hopende,blijkbaar verwacht men hier niet veel meer van, de ballonnetjes die men opgelaten heeft hebben ons gebracht waar we nu staan 25% dieper. Iedereen een beetje depri net als het weer. De aandeelhouders vergadering was ook al geen succes. We kunnen enkel hopen dat men profijt heeft kunnen maken van de sterke vraag naar de covid testen en dat de vraag naar hun nieuwe producten de verkoop van hun consoles een boost gekregen heeft. Zodoende de cashburn een halt toegeroepen wordt. Zit hier nu ook al een poosje in maar mijn geduld heeft ook zijn grenzen. Hopende op betere tijden.
Na bijna 3 uur handel,maar 5000 aandelen verhandeld! Koers al weken dood, handel op een dieptepunt,rijp om van de beurs te halen.
CGCDLR schreef op 24 juni 2021 11:46 :
Na bijna 3 uur handel,maar 5000 aandelen verhandeld! Koers al weken dood, handel op een dieptepunt,rijp om van de beurs te halen.
Zouden ze eind juli niet eens de stand van zaken doorgeven hoe hun bestellingen zitten van de verkoop
Nieuws op komst? Vacature voor Manager regulatory affairs , Europa,VS.
CGCDLR schreef op 1 juli 2021 12:26 :
Nieuws op komst? Vacature voor Manager regulatory affairs , Europa,VS.
Is de een extra functie of is het een vervanger
Waarschijnlijk een nieuwe functie.
Qiagen forms strategic alliance with Sysmex for cancer compagnon blijkbaar beweegt er toch iets in de sector.Hopelijk valt Biocartis (weer) niet uit de boot!??
twitter.com/Immunexpress?ref_src=twsr... Immunexpress is presenting clinical data in a late-breaking abstract, demonstrating the performance of SeptiCyte® RAPID in #COVID19 positive patients, at the 31st European Congress of Clinical Microbiology & Infectious Diseases- #ECCMID2021 July 9-12 This might be interesting. The previous presentations have been far from inspiring largely because while Septicyte Rapid appeared to identify many that would suffer respiratory distress requiring intubation, there were a few false positives and negatives. From my perspective, part of the problem may have been that respiratory failure and low oxygen levels was not necessarily the same as sepsis. If they have collected data to relate Septicyte Rapid results to the cytokine cascade that causes the immune system to way overreact causing sepsis it could demonstrate much greater test utility. FL
Thanks FL,do you still believe in a stand alone future for Biocartis?Qaigen forms alliance with Sysmex(cancer diagnostics).Quidel is also looking for purchasing a "competitor". There is a lot of movement in the sector,my opinion, sorry for my bad English.
www.businesswire.com/news/home/202107... It's obvious more investment will flow into companion diagnostic market. Biocartis already has partnership with Covance (CRO for Labcorp) and demand for efficient screening method for bio marker will increase. Watch this space
Man man wat is dat terug vandaag pff
Alle winst van meer dan een maand weggeveegd in 4 uur tijd. Je zou er moedeloos van worden. Aanleiding? Dumping door shorters? bij deze volumes lijkt dat niet onmogelijk. Of is er meer aan de hand ?
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee